Aller au contenu principal
xMedica

NCT07798726ClinicalTrials.gov

TransCatheter Replacement Of the Mitral Valve With the Novel Cephea Mitral Valve System

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The objective of this clinical trial is to evaluate the safety and effectiveness of the Cephea Mitral Valve System in subjects with symptomatic mitral valve disease (MVD) or are deemed unsuitable for surgery and transcatheter repair.

Interventionnelle565 participants recherchés1 site1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-09-01; recorded start 2026-10-21
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 85 other studies in this databaseCounted from the lead sponsor named in the record (Abbott Medical Devices)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 9 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 565 participants (target), run at 1 site.

How this score is built
  • Enrolment27/40

    565 participants (target)

  • Site count0/25

    1 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 112 months

  • Sponsor scale7/10

    Abbott Medical Devices has led 86 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The objective of this clinical trial is to evaluate the safety and effectiveness of the Cephea Mitral Valve System in subjects with symptomatic mitral valve disease (MVD) or are deemed unsuitable for surgery and transcatheter repair.

This is a global, prospective interventional multi-center study.

Affections

  • Mitral Valve Disease
  • Mitral Annulus Calcification
  • Mitral Regurgitation
  • Mitral Stenosis
  • Mitral Valve (MV) Regurgitation
  • Mitral Valve Replacement
  • Transcatheter Valve Replacement
  • Mitral Valve Insufficiency
  • Heart Valve Disease

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: 1. Mitral valve dysfunction meeting one of the following severity criteria: a. Mitral Annular Calcification (MAC) associated with at least one of the following: i. Grade III or higher mitral regurgitation (MR) ii. Severe mitral stenosis (MS) iii. Concomitant moderate (Grade II) MR and moderate MS b. Grade III or higher MR of primary or secondary etiology 2. The subject is deemed unsuitable for both conventional mitral valve surgery and transcatheter mitral valve repair 3. NYHA functional class II or higher 4. Left Ventricular Ejection Fraction of at least 25% 5. Left Ventricular End Diastolic Dimension ≤ 75mm 6. The Site Heart Team determines that the subject has been adequately treated per applicable standards for coronary artery disease, left ventricular dysfunction, cardiac arrhythmias, and heart failure 7. 18 years of age or older 8. The subject agrees to the study requirements and has provided written informed consent Exclusion Criteria: 1. Currently participating in another investigational drug or device study that has not reached its primary endpoint. 2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's safety or ability to participate in the clinical investigation or to comply with the follow-up requirements, or impact the scientific soundness of the clinical investigation results. 3. Prior surgical or interventional treatment that can interfere with the Cephea Valve delivery or function 4. Iliofemoral venous anatomy that is insufficient for the introduction and delivery of the Cephea Valve or Delivery System 5. Any planned cardiac surgery or intervention within the next 12 months 6. Any planned surgery in the next 12 months that is expected to adversely impact mobility or the subject's quality of life 7. Imaging evidence of intracardiac mass, vegetation, or thrombus at risk of embolization 8. Moderate or severe aortic stenosis, or aortic valve disease requiring surgery or transcatheter intervention 9. Severe tricuspid or pulmonary valvular regurgitation, or valve disease requiring surgery or transcatheter intervention 10. Evidence of right-sided congestive heart failure or severe right ventricular dysfunction 11. Subject is undergoing dialysis or has chronic renal failure 12. Subject has fixed pulmonary arterial hypertension 13. Moderate to severe liver disease 14. Prior orthotopic heart transplantation 15. Unresolved severe carotid stenosis, or symptomatic carotid stenosis of any severity 16. Hypertrophic or restrictive cardiomyopathy, or constrictive pericarditis that would interfere with Cephea Valve fit or function 17. Known hypersensitivity or contraindication to procedural or post-procedural medications that cannot be adequately managed 18. Known hypersensitivity to nickel or titanium that cannot be appropriately managed 19. Transesophageal echocardiography (TEE) is contraindicated or high risk 20. Chronic lung disease requiring continuous home oxygen therapy 21. Modified Rankin Scale ≥ 4 disability 22. Subject is pregnant or nursing and those who plan pregnancy during the clinical investigation follow-up period

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhaseSans objet
RépartitionNon randomisée
Modèle d'interventionSINGLE_GROUP
Objectif principalTREATMENT
InsuNONE (0)
Recrutement565 participants recherchés

Promoteur et collaborateurs

  • Abbott Medical Devices Promoteur

Groupes et interventions

  • Mitral Regurgitation CohortEXPERIMENTAL

    Inclusive of subjects who have moderate-to-severe or severe Mitral Regurgitation

  • Mitral Annular Calcification (MAC) CohortEXPERIMENTAL

    Inclusive of subjects with mitral valve dysfunction associated with MAC

Interventions

  • Dispositif Cephea Mitral Valve System

    During the transcatheter mitral valve replacement procedure, the Cephea Mitral Valve will be placed via transseptal approach

Critères de jugement

  1. Critère de jugement principal

    Primary Effectiveness Endpoint

    Freedom from all-cause mortality and heart failure hospitalization

    Délai 12 months post index procedure.

  2. Critère de jugement principal

    Primary Safety Endpoint

    Incidence rate of the composite event of cardiovascular death, stroke, life-threatening bleeding, valve thrombosis, or paravalvular leak with hemolysis.

    Délai 30 days post index procedure

  3. Critère de jugement secondaire

    Change in mitral regurgitation severity from baseline as assessed by the echocardiography core laboratory.

    Mitral regurgitation will be graded on a scale from None (least) to Grade IV (most).

    Délai 12 months post index procedure

  4. Critère de jugement secondaire

    Change in Quality of Life from baseline as measured by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score

    The overall summary score can range from 0-100, with higher scores representing a better quality of life.

    Délai 12 months post index procedure

  5. Critère de jugement secondaire

    Change in the New York Heart Association Functional Classification of at least one grade from baseline.

    New York Heart Association (NYHA) Functional Classification places patients in one of four classes based on their physical activity limitations, with Class I representing the least severe symptoms and increasing classifications representing more severe symptoms. Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort

    Délai 12 months post index procedure

Dates

Dates
Date de début21 octobre 2026 (réelle)
Achèvement principal31 décembre 2031 (estimée)
Achèvement31 décembre 2035 (estimée)
Première publication1 septembre 2026 (réelle)
Dernière mise à jour13 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisnovembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

1 site est en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Ascension Via Christi Hospitals WichitaWichitaKansasEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 13 novembre 2026

    Statut modifié

    Status changed from Unknown to Recruiting

    UNKNOWNRECRUITING

  2. 13 novembre 2026

    Recrutement ouvert

    Recruitment opened

    UNKNOWNRECRUITING

  3. 13 novembre 2026

    Site ajouté

    1 site added (1 total)

    01